Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Brief Summary: This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether the standard adjuvant therapy of cyclophosphamide and doxorubicin hydrochloride is more effective than paclitaxel in treating women with breast cancer


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: methotrexate, Drug: 5-fluorouracil | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): A
B: Arm Label: Arm A Taxane-containing; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Arm B standard anthracyclin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): Arm A Taxane-containing, Arm B standard anthracyclin
C: Arm Label: Arm A: FAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-fluorouracil, Drug: Doxorubicin, Drug: Cyclophosphamide | Arm Label: Arm B: TAC; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Doxorubicin, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: TAC | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Arm A: FAC | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A: FAC, Arm B: TAC | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A: FAC, Arm B: TAC
D: Arm Label: Arm I (CA for 4 courses); Type: ACTIVE_COMPARATOR; Interventions: Drug: AC regimen, Drug: doxorubicin hydrochloride | Arm Label: Arm II (CA for 6 courses [closed to accrual 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride | Arm Label: Arm III (paclitaxel for 4 courses); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Arm Label: Arm IV (paclitaxel for 6 courses [closed 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Intervention Type: DRUG; Name: AC regimen; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]), Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007]) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007])

Answer: D